ISRCTN96315193 https://doi.org/10.1186/ISRCTN96315193

Comparison of the effect of Erythropoietin, L-Carnitine and Erythropoietin plus L-Carnitine in correction of anemia in chronic haemodialysis patients

Submission date
07/08/2005

Recruitment status
No longer recruiting

Registration date
11/08/2005

Overall study status
Completed

Last Edited
25/09/2009

Condition category
Urological and Genital Diseases

[_] Prospectively registered
[_] Protocol
[_] Statistical analysis plan
[_] Results
[_] Individual participant data
[_] Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Hamid Tayebi Khosroshahi

Contact details
Dialysis Center
Imam Hospital
Daneshgah Street
Tabriz
Iran
+98 411 3344339
drtayebikh@yahoo.com

Additional identifiers

Study information

Scientific Title

Acronym
Carnitine-Epo

Study objectives
Anemia in chronic haemodialysis patients is improved by administration of Erythropoietin or L-Carnitine or Erythropoietin plus L-Carnitine.

Ethics approval required
Old ethics approval format

Ethics approval(s)
Not provided at time of registration

Primary study design
Interventional

Study design
Randomised controlled trial

Study type(s)
Treatment

Health condition(s) or problem(s) studied
Chronic Renal Failure (End-Stage Renal Disease [ESRD])

Interventions
1. Administration of rHu-EPO 4000 IU/week, subcutaneously (SC) (2000 IU, twice weekly) for 3 months (N = 20)
2. Administration of L-Carnitine 500 mg/day, orally, for 3 months (N = 15)
3. Administration of rHu-EPO 4000 IU/week, SC PLUS L-Carnitine 500 mg/day, orally, for 3 months (N = 15)

Intervention Type
Drug

Phase
Not Specified

Drug/device/biological/vaccine name(s)
Erythropoietin, L-Carnitine

Primary outcome(s)
Haemoglobin level

Key secondary outcome(s)
Not provided at time of registration

Completion date
01/03/2005

Eligibility

Key inclusion criteria
1. Dialysis for more than 6 months
2. Hb less than 11 g/dl

Participant type(s)
Patient

Healthy volunteers allowed
No

Age group
Adult

Sex
All

Key exclusion criteria
1. Active infectious disease
2. Active bleeding disorders

Date of first enrolment
01/03/2003

Date of final enrolment
01/03/2005

Locations

Countries of recruitment
Iran

Study participating centre
Dialysis Center
Tabriz
Iran

Sponsor information

Organisation
Tabriz University of Medical Sciences (Iran)

ROR
https://ror.org/04krpx645

Funder(s)

Funder type
University/education

Funder Name
Tabriz University of Medical Sciences (Iran)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration